Medical Access and Reimbursement in Austria

Psilocybin and psilocin are listed in Annex V.1 of Austria's narcotic substances regulation, and section 27 SMG expressly covers psilocybin- and psilocin-containing mushrooms in misuse-related contexts. The visible Austrian psilocybin signal is the Vienna anti-anhedonia imaging trial, not routine care. # # # #

MDMA is listed in Annex V.1. No Austrian market authorisation, routine medical access or public reimbursement route was identified outside authorised research. # #

Spravato is EMA-authorised and entered Austria's Erstattungskodex from 1 August 2024 under RE1 criteria for qualifying treatment-resistant depression patients. The criteria require specialist and hospital-linked initiation and reassessment, so this is a real but narrow reimbursement pathway. # # #

Racemic ketamine is clinically available as an authorised anaesthetic, and MedUni Vienna reports fast-acting antidepressant work around ketamine. Psychiatric use remains off-label and funding is less standardised than EKO-listed Spravato. # # #

DMT is listed in Annex V.1. No routine Austrian medical or reimbursement route was identified outside authorised research. #

No Austrian market authorisation, routine treatment route or public reimbursement pathway for 5-MeO-DMT was identified in reviewed sources. # # #

No Austrian authorised ibogaine treatment, reimbursement route or public compassionate-use programme was identified in reviewed sources. # #

No Austrian authorised medical or reimbursement route for ayahuasca was identified. DMT control remains relevant, and the reviewed compassionate-use list did not show a psychedelic programme. # #

Mescaline is listed in Annex V.1. No routine Austrian medical or reimbursement route was identified outside authorised research. #

No Austrian authorised treatment or reimbursement route for 2C-family substances was identified in reviewed sources. # #